|Original language||English (US)|
|Number of pages||4|
|Journal||American journal of respiratory and critical care medicine|
|State||Published - Dec 1 2018|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
Access to Document
Other files and links
Mucin concentrations and peripheral airway obstruction in chronic obstructive pulmonary disease. / SPIROMICS Investigative Group.In: American journal of respiratory and critical care medicine, Vol. 198, No. 11, 01.12.2018, p. 1453-1456.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Mucin concentrations and peripheral airway obstruction in chronic obstructive pulmonary disease
AU - SPIROMICS Investigative Group
AU - Kesimer, Mehmet
AU - Smith, Benjamin M.
AU - Ceppe, Agathe
AU - Ford, Amina A.
AU - Anderson, Wayne H.
AU - Barr, R. Graham
AU - O’Neal, Wanda K.
AU - Boucher, Richard C.
AU - Woodruff, Prescott G.
AU - Han, Mei Lan K.
AU - Hoffman, Eric A.
AU - Martinez, Fernando
AU - Curtis, Jeffrey L.
AU - Paine, Robert
AU - Cooper, Christopher B.
AU - Bleecker, Eugene R.
N1 - Funding Information: Supported by the Netherlands Organization for Scientific Research NWO (Domain Applied and Engineering Sciences; Perspectief program P12-04; projects: 13541 and 13544), Lung Foundation Netherlands (project: 6.2.15.044JO), and Noordelijke CARA Stichting (project: 2016/01). Author Contributions: Conception, design of study: S.D.P., F.K., M.K., P.H., R.B., and N.H.T.t.H. Acquisition and analysis of data: S.D.P., F.K., M.K., V.R.W., and A.F. Drafting of the manuscript: S.D.P. and F.K. Revision of manuscript: S.D.P., F.K., M.K., V.R.W., A.F., M.v.d.B., P.H., R.B., and N.H.T.t.H. Funding Information: Supported primarily by NHLBI grant R01HL110906 (M.K.) under the NHLBI Ancillary Studies in Clinical Trials program and by NIH grant R01HL130506 (B.M.S.). This study used sputum samples and data collected through SPIROMICS, which was supported by NHLBI contracts HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C. These contracts were supplemented by contributions made through the Foundation for the National Institutes of Health from AstraZeneca, Bellerophon Therapeutics, Boehringer Ingelheim Pharmaceuticals, Chiesi Farmaceutici, Forest Research Institute, GlaxoSmithKline, Grifols Therapeutics, Ikaria, Novartis Pharmaceuticals, Nycomed, Regeneron Pharmaceuticals, Sanofi, and Takeda Pharmaceutical Company.
PY - 2018/12/1
Y1 - 2018/12/1
UR - http://www.scopus.com/inward/record.url?scp=85057569562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057569562&partnerID=8YFLogxK
U2 - 10.1164/rccm.201806-1016LE
DO - 10.1164/rccm.201806-1016LE
M3 - Letter
C2 - 30130124
AN - SCOPUS:85057569562
VL - 198
SP - 1453
EP - 1456
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
SN - 1073-449X
IS - 11